Top

European Radiology

Published in:

01-02-2011 | Oncology

Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer

Authors: R. S. Gillies, M. R. Middleton, N. D. Maynard, K. M. Bradley, F. V. Gleeson

Published in: European Radiology | Issue 2/2011

Abstract

Objective

¹⁸F-fluorodeoxyglucose positron emission tomography (FDG PET) has been shown to improve the accuracy of staging in oesophageal cancer. We assessed the benefit of PET/CT over conventional staging and determined if tumour histology had any significant impact on PET/CT findings.

Methods

A retrospective cohort study, reviewing the results from 200 consecutive patients considered suitable for radical treatment, undergoing routine PET/CT staging comparing the results from CT and endoscopic ultrasound, as well as multi-disciplinary team records. Adenocarcinoma and squamous cell carcinoma were compared for maximum Standardised Uptake Value (SUV_max), involvement of local lymph nodes and distant metastases.

Results

PET/CT provided additional information in 37 patients (18.5%) and directly altered management in 34 (17%): 22 (11%) were upstaged; 15 (7.5%) were downstaged, 12 of whom (6%) received radical treatment. There were 11 false negatives (5.5%) and 1 false positive (0.5%). SUV_max was significantly lower for adenocarcinoma than squamous cell carcinoma (median 9.1 versus 13.5, p = 0.003).

Conclusions

Staging with PET/CT offers additional benefit over conventional imaging and should form part of routine staging for oesophageal cancer. Adenocarcinoma and squamous cell carcinoma display significantly different FDG-avidity.

van Vliet EP, Heijenbrok-Kal MH, Hunink MG et al (2008) Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 98:547–557CrossRefPubMed

Heeren PA, Jager PL, Bongaerts F et al (2004) Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med 45:980–987PubMed

Gananadha S, Hazebroek EJ, Leibman S et al (2008) The utility of FDG-PET in the preoperative staging of esophageal cancer. Dis Esophagus 21:389–394CrossRefPubMed

van Westreenen HL, Westerterp M, Sloof GW et al (2007) Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg 94:1515–1520CrossRefPubMed

Bar-Shalom R, Guralnik L, Tsalic M et al (2005) The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging 32:918–924CrossRefPubMed

Yuan S, Yu Y, Chao KS et al (2006) Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med 47:1255–1259PubMed

Berrisford RG, Wong WL, Day D et al (2008) The decision to operate: role of integrated computed tomography positron emission tomography in staging oesophageal and oesophagogastric junction cancer by the multidisciplinary team. Eur J Cardiothorac Surg 33:1112–1116CrossRefPubMed

Salahudeen HM, Balan A, Naik K et al (2008) Impact of the introduction of integrated PET-CT into the preoperative staging pathway of patients with potentially operable oesophageal carcinoma. Clin Radiol 63:765–773CrossRefPubMed

Kato H, Miyazaki T, Nakajima M et al (2005) The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 103:148–156CrossRefPubMed

10.

Lerut T, Flamen P, Ectors N et al (2000) Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 232:743–752CrossRefPubMed

11.

Flamen P, Lerut A, Van Cutsem E et al (2000) Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18:3202–3210PubMed

12.

Luketich JD, Schauer PR, Meltzer CC et al (1997) Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 64:765–769CrossRefPubMed

13.

Okada M, Murakami T, Kumano S et al (2009) Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer. Ann Nucl Med 23:73–80CrossRefPubMed

14.

Noble F, Bailey D, Tung K, Byrne JP (2009) Impact of integrated PET/CT in the staging of oesophageal cancer: a UK population-based cohort study. Clin Radiol 64:699–705CrossRefPubMed

15.

Roedl JB, Sahani DV, Colen RR et al (2008) Tumour length measured on PET-CT predicts the most appropriate stage-dependent therapeutic approach in oesophageal cancer. Eur Radiol 18:2833–2840CrossRefPubMed

16.

Kwee TC, Takahara T, Ochiai R et al (2008) Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol 18:1937–1952CrossRefPubMed

17.

Sakurada A, Takahara T, Kwee TC et al (2009) Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer. Eur Radiol 19:1461–1469CrossRefPubMed

18.

Meyers BF, Downey RJ, Decker PA et al (2007) The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 133:738–745CrossRefPubMed

19.

Westerterp M, Sloof GW, Hoekstra OS et al (2008) 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol 134:227–236CrossRefPubMed

20.

Kato H, Takita J, Miyazaki T et al (2003) Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma. Anticancer Res 23:3263–3272PubMed

21.

van Westreenen HL, Plukker JT, Cobben DC et al (2005) Prognostic value of the standardized uptake value in esophageal cancer. AJR Am J Roentgenol 185:436–440PubMed

22.

Hong D, Lunagomez S, Kim EE et al (2005) Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 104:1620–1626CrossRefPubMed

23.

Cerfolio RJ, Bryant AS (2006) Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 82:391–394, discussion 394–395CrossRefPubMed

Title: Additional benefit of 18F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer
Authors: R. S. Gillies
M. R. Middleton
N. D. Maynard
K. M. Bradley
F. V. Gleeson
Publication date: 01-02-2011
Publisher: Springer-Verlag
Published in: European Radiology / Issue 2/2011
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-010-1943-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer

Abstract

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2011

Intracranial cerebrospinal fluid spaces imaging using a pulse-triggered three-dimensional turbo spin echo MR sequence with variable flip-angle distribution

Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases

Diffusion tensor imaging and fibre tracking in cervical spondylotic myelopathy

Optimized intravenous Flat Detector CT for non-invasive visualization of intracranial stents: first results

High-resolution 3D non-contrast-enhanced, ECG-gated, multi-step MR angiography of the lower extremities: Comparison with contrast-enhanced MR angiography

Characterization of ex vivo healthy human axillary lymph nodes with high resolution 7 Tesla MRI